ClinicaliQ Trial Snapshot
- A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers — Recruiting • Phase I • Oncology • NCT07226843.
- What is being tested: LY4584180, a novel investigational agent, is being evaluated for its safety, efficacy, pharmacokinetics, and pharmacodynamics in adults with relapsed or refractory blood cancers (haematologic malignancies) who have exhausted standard treatment options.
- Patient eligibility overview: The trial enrolls adult patients with previously treated blood cancers who have progressed despite or become intolerant to conventional therapies; specific eligibility criteria regarding disease type, prior treatment lines, and organ function will be defined in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Eligibility Snapshot
- : * Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy: * Diffuse large B-cell lymphoma - not otherwise specified * High-grade B-cell lymphoma * Diffuse large B-cell lymphoma - transformed from indolent lymphomas * Follicular large B-cell lymphoma * Follicular lymphoma * Other non-Hodgkin lymphoma * Has measurable disease * Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.